A selective estrogen receptor modulator (SERM). Displays anti-estrogen action along with anti-androgen action. In clinical use for prevention of postmenopausal osteoporosis. Reduces circulating levels of IL-6 and TNFα. Inhibits prostate carcinogenesis in transgenic rat model. May be useful for the prevention of hormone-related cancers.
Product Details
| Formula: | C28H28ClNO4S |
| |
| MW: | 510 |
| |
| CAS: | 82640-04-8 |
| |
| Purity: | ≥98% (TLC) |
| |
| Identity: | Determined by 1H-NMR and MS. |
| |
| Appearance: | Pale green solid. |
| |
| Solubility: | Soluble in methanol. |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Store reconsitituted solutions at -20°C for up to three months. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Prevention of hormone-related cancers: breast cancer: B. K. Dunn, et al.; J. Clin. Oncol.
23, 357 (2005),
Abstract;
Raloxifene modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: results from a pilot clinical study: W. Gianni, et al.; J. Clin. Endocrinol. Metab.
89, 6097 (2004),
Abstract;
